• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Regulating medicines in Croatia: five-year experience of Agency for Medicinal Products and Medical Devices.克罗地亚的药品监管:药品和医疗器械局的五年经验
Croat Med J. 2010 Apr;51(2):104-12. doi: 10.3325/cmj.2010.51.104.
2
Generic Medicines in Croatia--Regulatory Aspects and Statistics.克罗地亚的仿制药——监管方面与统计数据
Coll Antropol. 2015 Jun;39(2):363-70.
3
The regulation of medical devices and the role of the Medical Devices Agency.医疗器械的监管及医疗器械局的作用。
Br J Clin Pharmacol. 2001 Sep;52(3):229-35. doi: 10.1046/j.0306-5251.2001.01416.x.
4
Impact of regulatory guidances and drug regulation on risk minimization interventions in drug safety: a systematic review.监管指南和药物监管对药物安全风险最小化干预措施的影响:系统评价。
Drug Saf. 2012 Jul 1;35(7):535-46. doi: 10.2165/11599720-000000000-00000.
5
Good manufacturing practice: the role of local manufacturers and competent authorities.良好生产规范:当地制造商和主管当局的作用
Arh Hig Rada Toksikol. 2010 Dec;61(4):425-36. doi: 10.2478/10004-1254-61-2010-2035.
6
Adverse drug reactions of psycopharmacs.精神药物的药物不良反应。
Psychiatr Danub. 2010 Sep;22(3):441-5.
7
Medical device regulation for manufacturers.针对制造商的医疗器械监管
Proc Inst Mech Eng H. 2003;217(6):459-67. doi: 10.1243/09544110360729090.
8
African Medicines Agency to be established.非洲药品管理局即将成立。
Lancet. 2021 Oct 23;398(10310):1475. doi: 10.1016/S0140-6736(21)02310-2.
9
Mutual recognition in the European system: A blueprint for increasing access to medicines?欧洲体系中的相互承认:增加药品可及性的蓝图?
Regul Toxicol Pharmacol. 2019 Aug;106:270-277. doi: 10.1016/j.yrtph.2019.05.004. Epub 2019 May 7.
10
Fighting trafficking of falsified and substandard medicinal products in Russia.打击俄罗斯假药和劣药的非法交易。
Int J Risk Saf Med. 2015;27 Suppl 1:S37-40. doi: 10.3233/JRS-150681.

引用本文的文献

1
Quality analysis of manufacturer's incident reports regarding medical devices.医疗器械制造商事件报告的质量分析
J Pharm Policy Pract. 2023 Jan 16;16(1):3. doi: 10.1186/s40545-023-00519-2.
2
Comparing pharmaceutical pricing and reimbursement policies in Croatia to the European Union Member States.将克罗地亚的药品定价和报销政策与欧盟成员国进行比较。
Croat Med J. 2011 Apr 15;52(2):183-97. doi: 10.3325/cmj.2011.52.183.

本文引用的文献

1
Factors associated with success of market authorisation applications for pharmaceutical drugs submitted to the European Medicines Agency.与向欧洲药品管理局提交的药品市场授权申请成功相关的因素。
Eur J Clin Pharmacol. 2010 Jan;66(1):39-48. doi: 10.1007/s00228-009-0756-y. Epub 2009 Nov 20.
2
The licensing of medicines in the UK.英国药品的许可情况。
Drug Ther Bull. 2009 Apr;47(4):45-8. doi: 10.1136/dtb.2009.03.0012.
3
Clinical evaluations clinical investigations under the amended Medical Device Directive.根据修订后的《医疗器械指令》进行的临床评估和临床调查。
Med Device Technol. 2008 Sep;19(5):16-8, 20.
4
Balancing early market access to new drugs with the need for benefit/risk data: a mounting dilemma.在新药的早期市场准入与获取效益/风险数据的需求之间取得平衡:一个日益严峻的困境。
Nat Rev Drug Discov. 2008 Oct;7(10):818-26. doi: 10.1038/nrd2664. Epub 2008 Sep 12.
5
[The role of the Committee for Medicinal Products for Human Use (CHMP) in the European centralised procedure].人用药品委员会(CHMP)在欧洲集中程序中的作用
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2008 Jul;51(7):731-9. doi: 10.1007/s00103-008-0579-5.
6
[The implementation of European directives into national law, demonstrated by the example of the EC Tissues and Cells Directive 2004/23/EC].[以欧盟《人体组织和细胞指令》(2004/23/EC)为例说明欧洲指令在国内法中的实施情况]
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2008 Jul;51(7):757-63. doi: 10.1007/s00103-008-0582-x.
7
[Registration of new medicinal products in Europe].[欧洲新药品注册]
Onkologie. 2008;31 Suppl 2:64-6. doi: 10.1159/000113448. Epub 2008 Apr 18.
8
Provision of information on regulatory authorities' websites.在监管机构网站上提供信息。
Intern Med J. 2008 Jul;38(7):559-67. doi: 10.1111/j.1445-5994.2007.01588.x. Epub 2008 Mar 11.
9
How to anticipate the assessment of the public health benefit of new medicines?如何预测对新药公共卫生效益的评估?
Therapie. 2007 Sep-Oct;62(5):427-35. doi: 10.2515/therapie:2007071. Epub 2008 Jan 19.
10
Who is responsible for evaluating the safety and effectiveness of medical devices? The role of independent technology assessment.谁负责评估医疗设备的安全性和有效性?独立技术评估的作用。
J Gen Intern Med. 2008 Jan;23 Suppl 1(Suppl 1):57-63. doi: 10.1007/s11606-007-0275-4.

克罗地亚的药品监管:药品和医疗器械局的五年经验

Regulating medicines in Croatia: five-year experience of Agency for Medicinal Products and Medical Devices.

作者信息

Tomić Sinisa, Filipović Sucić Anita, Plazonić Ana, Truban Zulj Rajka, Macolić Sarinić Viola, Cudina Branka, Ilić Martinac Adrijana

机构信息

Agency for Medicinal Products and Medical Devices, Ksaverska cesta 4, 10000 Zagreb, Croatia.

出版信息

Croat Med J. 2010 Apr;51(2):104-12. doi: 10.3325/cmj.2010.51.104.

DOI:10.3325/cmj.2010.51.104
PMID:20401952
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2859415/
Abstract

AIM

To present the activities of the Agency for Medicinal Products and Medical Devices in the first 5 years of its existence and to define its future challenges.

METHODS

Main activities within the scope of the Agency as a regulatory authority were retrospectively analyzed for the period from 2004-2008. Data were collected from the Agency's database and analyzed by descriptive statistics.

RESULTS

The number of issued medicine authorizations rose from 240 in 2004 to 580 in 2008. The greatest number of new chemical and biological entities was approved in 2005. The greatest number of regular quality controls (n=5833) and special quality controls was performed in 2008 (n=589), while the greatest number of off-shelf quality controls (n=132) was performed in 2007. The greatest number of medicine labeling irregularities was found in 2007 (n=19) and of quality irregularities in 2004 (n=9). The greatest number of adverse reactions was reported in 2008 (n=1393). The number of registered medical devices rose from 213 in 2004 to 565 in 2008.

CONCLUSION

Over its 5 years of existence, the Agency has successfully coped with the constant increase in workload. In the future, as Croatia enters the European Union, the Agency will have to face the challenge of joining the integrated European regulatory framework.

摘要

目的

介绍药品和医疗器械局成立头5年的活动,并明确其未来面临的挑战。

方法

对2004年至2008年期间该局作为监管机构范围内的主要活动进行回顾性分析。数据从该局数据库收集,并通过描述性统计进行分析。

结果

发放的药品授权数量从2004年的240份增至2008年的580份。2005年批准的新化学实体和生物实体数量最多。2008年进行的常规质量控制数量最多(n = 5833),特殊质量控制数量最多(n = 589),而2007年进行的下架质量控制数量最多(n = 132)。2007年发现的药品标签违规数量最多(n = 19),2004年发现的质量违规数量最多(n = 9)。2008年报告的不良反应数量最多(n = 1393)。注册医疗器械数量从2004年的213件增至2008年的565件。

结论

在其成立的5年里,该局成功应对了工作量的不断增加。未来,随着克罗地亚加入欧盟,该局将不得不面对加入欧洲综合监管框架的挑战。